ArticleCytoJournal2025
Human immunodeficiency virus negative, immunocompetent primary effusion lymphoma with a complete response on R-miniCHOP.
Article in CytoJournal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary effusion lymphoma (PEL) is a rare kind of extranodal non-Hodgkin large B-cell lymphoma that develops in the liquid phase in serous membrane-lined body cavities (perineum, pericardium, and pleura) without tumor masses. Kaposi sarcoma-associated human herpesvirus 8 (HHV8) is essential in establishing a diagnosis of PEL. An 84-year-old male with a past medical history of testicular cancer in his 40s presented with a chief complaint of shortness of breath which was attributed to a left pleural effusion. The flow cytometry indicated 32% small T lymphocytes (cluster of differentiation [CD]4: CD8 = 4.0:1), 9.0% small B lymphocytes without surface light chain expression, and 16% unknown phenotypic large cells. The cell block demonstrated large atypical lymphocytes with irregular nuclear membranes and coarse chromatin. The cells exhibited prominent nucleoli and relatively basophilic, abundant amphophilic cytoplasm. Multinucleated and Reed-Sternberg-like cells were also seen. We performed a panel of immunomarkers including HHV8 and ALK1. The tumor cells were positive for CD45, CD20, and HHV8 and negative for all other markers. Based on morphologic and immunophenotypical features, a diagnosis of PEL is rendered. Positron emission tomography/computed tomography showed an absence of fluorodeoxyglucose uptake in the lymph nodes and the spleen. Given his age, the patient started on treatment with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone at reduced doses (R-miniCHOP) and had a complete response. To our knowledge, there are no other reported cases of complete remission following an attenuated R-miniCHOP protocol in this clinical scenario.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.